TCT 2021 | SUGAR Trial: Polymer-Free Stent in Diabetes

In CAD patients with diabetes the polymer-free amphilimus-eluting stent resulted non-inferior to the polymer-based zotarolimus-eluting Resolute Onyx.

TCT 2021 | SUGAR Trial: Stent libre de polímero en diabetes

This new device, in addition to ultrathin struts, has already been found non-inferior to the Resolute Integrity in the general population at 3-year followup. Researchers believe that the new amphiphilic carrier might be especially useful in diabetic patients given its greater diffusion along the arterial walls. 

This hypothesis has generated the present study called SUGAR, presented in the scientific sessions at TCT 2021 and simultaneously published in the European Heart Journal.

The new device compared against the Resolute Onyx has shown 35% relative risk reduction of the combined end point (p<0.0001 for non-inferiority). An exploratory analysis has even shown superiority (p=0.03).

Despite these results, the authors still admit to the Onyx’s capacity to go through calcified, tortuous, or long lesions. 

The SUGAR included 1175 diabetic patients with no clinical presentation, complexity, or lesion number limitation. The study even included patients with left main lesion. Half of these patients have multivessel disease. 


Read also: AFIRE Trial: Atrial Fibrillation and PCI. What is the Ideal Therapy?


586 patients were randomized to receiving the Cre 8 EVO (this new device) and 589 to receiving Resolute Onyx.

After one-year followup, target vessel failure rate resulted 7.2% for the Cre8 EVO vs 10.9% for Onyx.

The advantage was mainly driven by revascularization as of 7 or 8 months in the Onyx arm.


Read also: Atrial Fibrillation and Dementia: Which Anticoagulant Agent Presents the Lowest Risk?


Even though the evidence is quite compelling, we still have a long way to go before considering this the new standard for diabetics. 

libre-de-polímero-en-DBT

Original Title: Amphilimus- versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease (SUGAR trial).

Reference: Rafael Romaguera et al. Eur Heart J. 2021 Nov 4;ehab790. Online ahead of print. doi: 10.1093/eurheartj/ehab790. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...